Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Featured trial
A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. EXSCEL Trial, Protocol BCB109.

A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. EXSCEL Trial, Protocol

  • 156 views
  • 25 Mar, 2021
  • 1 location
Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" (TOLEDDO)

, the most recent and most potent GLP1 agonist (superiority demonstrated compared to exenatide LP and dulaglutide) and administered as a weekly subcutaneous injection (in contrast to liraglutide

  • 0 views
  • 24 Jul, 2022
  • 1 location
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (GAPP-SVD)

Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials. The …

  • 0 views
  • 27 Jul, 2022
  • 1 location
GLP-1 and Hyperoxia for Organ Protection in Heart Surgery (GLORIOUS)

investigating the organ protective effects of the glucagon-like-peptide-1 (GLP-1) agonist Exenatide versus placebo and restrictive versus liberal oxygenation during weaning from cardio-pulmonary bypass.

byetta
percutaneous coronary intervention
exenatide
arterial disease
ischemic heart disease
  • 40 views
  • 27 Jan, 2022
  • 1 location
Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

This study is to evaluate the concept of the exenatide test for diagnosis of EHH (earlier induction of symptomatic hypoglycemia compared to placebo within 4 hours after injection).

  • 0 views
  • 10 Jun, 2021
  • 1 location
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.

glucagon
dapagliflozin
metformin
exenatide
sglt2
  • 67 views
  • 11 May, 2022
  • 1 location
Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Glucagon, exenatide and 0.9% saline will be intravenously infused, both in

Accepts healthy volunteers
  • 0 views
  • 08 Jan, 2022
  • 1 location
Brain Activation and Satiety in Children 2

behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon) in order to improve obesity intervention

  • 0 views
  • 09 Sep, 2021
  • 1 location
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants With Type 2 Diabetes (COCONUT)

The study seeks to explore the cardiovascular effects of co-agonism at the glucagon and (glucagon-like peptide-1) GLP-1 receptor. Glucagon and exenatide will be intravenously infused into

glucagon
metformin
exenatide
diabetes
glucagon-like peptide-1
  • 0 views
  • 23 Mar, 2022
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care: a Double-blind, Cross-over, Randomized Controlled Trial (SEMA-AP)

type 1 diabetes (such as liraglutide and exenatide), but are not as strong in glucose effect even in type 2 diabetes as compared with semaglutide. The purpose of our study is to see if

  • 0 views
  • 15 Sep, 2022
  • 1 location